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CardiomyogenesisStem cell therapy has been considered a promise for damaged myocardial tissue. We have previously shown
that S-nitroso-N-acetyl-D,L-penicillamine (SNAP) increases the expression of several muscular markers and
VEGF in mesenchymal stem cells, indicating that transplantation of SNAP-treated cells could provide better
functional outcomes. Here, we transplanted SNAP-treated adipose tissue-derived stem cells (ADSCs) in rat
infarcted myocardium. After 30 days, we observed a signiﬁcant improvement of the ejection fraction in rats
that received SNAP-treated ADSCs, compared with those that received untreated cells (p=0.008).
Immunohistochemical reactions showed an increased expression of troponin T–C and von Willebrand factor,
and organized vascular units in the infarcted area of tissue transplanted with treated ADSCs. SNAP exposure
induced intracellular S-nitrosation, a decreased GSH/GSSG ratio, but did not increase cGMP levels.
Collectively, these results indicate that SNAP alters the redox environment of ADSCs, possibly associated
with a pre-differentiation state, which may improve cardiac function after transplantation.a Básica, room 153, Setor de
eral do Paraná, Curitiba 81531-
vier OA license.© 2010 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Heart failure is the main cause of hospitalization in the United
States. Despite the decline of mortality its prevalence continues to
increase, mainly due to effectiveness of clinical treatment and aging of
the population (Schocken et al., 2008).
In recent years several studies have demonstrated the potential of
stem cells in tissue regeneration with the possibility of cardiac
function improvement after transplantation (Al-Radi et al., 2003;
Anversa et al., 2003; Orlic et al., 2002; Pittenger et al., 1999; Pittenger
and Martin, 2004). The mechanisms by which these cells promote
repair of myocardial damage are not well known. However, the idea
that stem cells could promote myocardium regeneration by means of
the transdifferentiation seems insufﬁcient. For this reason compli-
mentary mechanisms should be considered such as paracrine events
and neovascularization (Korbling and Estrov, 2003).Conceptually, a variety of stem cells can be used for myocardium
regeneration (Boyle et al., 2006). Mesenchymal stem cells (MSCs)
were ﬁrst described by Friedenstein et al. (1970). Their main function
is maintenance and renewal of adult mesenchymal tissue. These cells
can be harvested from diverse sources (Fukuda, 2005; Korbling and
Estrov, 2003;Wollert and Drexler, 2005) and although the similarities
described, differences in the expression of some genes and in
differentiation potential (Dominici et al., 2006; Rebelatto et al.,
2008) should be considered to choose the best source for each
determined transplant (Dai et al., 2005).
Adipose-derived stem cells (ADSCs) show similar characteristics
to bone marrow mesenchymal stem cells (BM-MSCs). Furthermore,
they are easily obtained, are present at a high frequency (0.5%),
and are able to differentiate into various lineages (Zuk et al., 2002).
Planat-Benard et al. (2004) observed that these cells can spontane-
ously differentiate and express transcription factors of cardiac cells.
The ADSCs also express cardiac tissue proteins and have the ability to
repair myocardial infarction (Strem et al., 2005), emphasizing the
possibility of their use in cellular therapy (Jiang et al., 2002).
The in vitro differentiation of ADSCs in cardiomyocytes requires the
addition of an inductive agent of differentiation.Nitric oxide (NO) induces
the differentiation of embryonic stem cells in cardiomyocytes (Kanno
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DEA/NO (2-(N,N-diethylamino)-diazenolate-2-oxide) and SNAP (S-
nitroso-N-acetyl-D,L-penicillamine), increase the expression of muscular
and cardiac markers, VEGF and CD34 in BM-MSCs and ADSCs (Rebelatto
et al., 2009), which might improve their effects in cellular therapy.
Here, we show that transplantation of SNAP-treated ADSCs in a rat
model of myocardial infarction improves the cardiac ejection fraction
when compared to transplantation of untreated ADSCs. The expres-
sion of troponins and von Willebrand factor, as well as the number of
blood vessels in the infarcted area, are also increased in SNAP-treated
cells transplantation. In vitro experiments indicate that SNAP triggers
an early intracellular protein S-nitrosation and an oxidative redox
state in ADSCs, which may be involved in observed beneﬁcial effects.
Material and methods
Experimental animals and study design
All procedures were performed after approval by the Human and
Animal Ethics Committees of Pontifícia Universidade Católica of Paraná
(approval numbers 597 and 202, respectively). Myocardial infarction
was induced in 60 male Wistar rats (200–230 g). Echocardiography
was performed 7 days later for determination of ventricular function.
On the eighth day, 33 rats presented ventricular ejection fraction
below 40%. Eight rats died after randomization, and the remainder
myocardial-infarcted animals underwent cell transplantation
(n=21) or injection of medium (control, n=4). Five additional rats
died after transplantation, and the rest were kept alive for 4 weeks,
without immunosuppression. Some animals were transplanted with
ADSCs previously transduced with GFP gene.
Infarct induction
All rats that underwent myocardial infarction were given general
anesthesia of intramuscular ketamine (50 mg/kg, Ketamine™, Labor-
atórios König SA, Brazil) and xylazine (10 mg/kg, Sintec, Rhobiofarma,
Brazil). These animals were endotracheally intubated with a ﬂexible
catheter (Abocath), and mechanically ventilated by using a small
animal ventilator (HARVARD®, Inc., model 683, Massachusetts, USA).
A left lateral thoracotomy was performed via the fourth intercostal
space to expose the heart. The anterior descending coronary artery
was localized, and ligated with a 7.0 non-absorbable Prolene suture
(Ethicon, Brazil) just proximal to the bifurcation of the left coronary.
The infarction was veriﬁed by the observed myocardial blanching
distal to the ligation. The thorax was then sutured and the animals
were monitored until they fully recovered from the anesthesia.
Echocardiography
Echocardiography was performed on the seventh day post-infarc-
tion and on the thirtieth day after cell transplantation. After anesthesia,
by intramuscular injection, a two-dimensional transthoracic echocar-
diography was performed with an echocardiography system equipped
with a 12-MHz phased-array transducer HP Sonos 5500 (Hewlett
Packard, USA) with the use of a speciﬁc transducer for small animals (S
12 5–12 mHz linear 15 L6 7–15 mHz) in the anterolateral portion of the
left lateral chest wall. The imageswere observed in two dimensions and
ventricular chambers observed in two sections, longitudinal and
transverse. Ejection fraction, end systolic and diastolic volume of the
left ventricle, and theendsystolic anddiastolic area of left ventriclewere
analyzed by the Simpson's method. The study included animals that
presented an ejection fraction of below40% on the echocardiography on
the seventh day after infarction. All measurements were performed on
the same equipment and repeated three times by the same observer.
The results are presented as the mean of three independent
measurements.Cell culture
ADSCs were isolated using the technique described by Puissant
et al. (2005) with modiﬁcations. Primary human ADSCs were isolated
and characterized as MSC as described elsewhere (Rebelatto et al.,
2008) from subjects undergoing elective bariatric surgery and
dermolipectomy procedures at the Instituto de Cirurgia e Medicina do
Paraná. Patient consent was acquired prior to surgery. A cohort of 3
samples was used for cell culture and transplantation.
Transduction of ADSCs by lentivirus and ﬂow cytometry
Four days prior to transplantation, ADSCs were transduced by a
third-generation lentivirus containing the green ﬂuorescent protein
(GFP) gene. The lentiviral particles were kindly provided by the
Institute of Molecular Biology of Parana (IBMP, Curitiba-PR, Brazil).
Transductions were performed by a single exposure of lentivirus in
the presence of 5 μg/ml of polybrene and a multiplicity of infection
(MOI) of 5. Twenty-four hours after transduction the medium with
the exceeding viruses was removed and the cells were maintained in
standard culture media until transplanted.
The percentage of positive cells for the GFP gene was assessed by
ﬂow cytometry. Cells were trypsinized, washed twice with PBS
solution and ﬁxed in 300 μL of 1% paraformaldehyde (PFA) (Merck,
Darmstadt, Germany) in PBS. The evaluation was immediately
performed in a FACS Calibur equipment (Becton Dickinson, San Jose,
CA, USA) and data were analyzed by FlowJo software (Tree Star,
Ashland, OR, USA).
ADSCs treatment with nitric oxide donor SNAP
This work employed two types of experiments with ADSCs. 1) For
the transplantation, following the establishment in culture of a
homogeneous population of ADSCs (fourth passage), 0.4 mM SNAP
(Calbiochem, CA, USA) was added in the ﬁrst and third days and
maintained until the fourth day. After this period, the cells remained
for a further 16 days with medium without addition of SNAP. The
medium was changed every two days until the twentieth day,
when cells were prepared for the transplantation. 2) To analyze the
effects of SNAP exposure to the ADSCs, cells were seeded at a density
1×105/cm2. After adhesion, they were grown in medium containing
1% fetal calf serum for 24 h and then treated with 0.2 mM SNAP in
medium containing 5% fetal calf serum (Gibco, Invitrogen Corpora-
tion, NY, USA) during 40 min.
Cell transplantation
Cell transplantation was performed 24 h after the determination
of ventricular function by echocardiography. Rats underwent general
anesthesia, a median thoracotomywas performed, and 1×106 ADSCs
were resuspended in 300 μL of DMEM-F12 medium and injected
using a tuberculin syringe with a needle into one point of the
myocardium (left ventricle), speciﬁcally in the center of the scar
covering the whole infarcted and peri-infarcted area. The animals
were divided into three experimental groups: (A) 4 animals
transplanted with medium (control group); (B) 11 rats transplanted
with ADSCs treated with SNAP, and (C) 10 rats transplanted with
ADSCs.
Animal euthanasia, perfusion-ﬁxation of the heart
After 30 days of the transplant, the animals were euthanized under
sedation, as described above. Brieﬂy, the left ventricle was cannulated
with a catheter connected to an infusion pump, and approximately
100 mL of a saline solution, followed by 400 mL of 2% PFA were
infused. At the end of the infusion, the heart was removed and
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Fig. 1. Mean pre- and post-transplant ejection fraction. Myocardial infarcted rats were
divided in groups A (control), B (animals transplanted with ADSCs treated with SNAP)
and group C (animals transplanted with untreated ADSCs). Their mean cardiac ejection
fractions (annotated above the bars) were determined by echocardiography one day
before (white bars) and thirty days after (black bars) the cell transplant. Ejection
fractions are presented as mean±SE in the box area and mean±SD in Whisker plot.
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the infarcted region was ﬁxed with 4% PFA for 24 h. Subsequently, the
sections were immersed in three solutions of sucrose (Biotec, Paraná,
Brazil) 10%, 20% and 30% in phosphate buffer (Gibco, Invitrogen
Corporation, NY, USA) 0.1 M, pH 7.4, embedded and frozen in a block
of cryopreservation medium of optimal cutting temperature (OCT)
(Sakura Finetek, Zoeterwoude, The Netherlands) in liquid nitrogen,
and stored at −80 °C.
Immunohistochemistry
For immunohistochemistry, cryosections of 5–7 μm were
obtained. Tissue sections were washed three times with a solution
of 10 mM TBS (Invitrogen, CA) containing 0.1% triton for 5 min. The
specimens were blocked with 10 mM TBS containing 0.1% triton
(Nuclear, São Paulo) and 5% goat serum (Gibco, Invitrogen Corpora-
tion, NY, USA) for 1 h. Subsequently, sections were incubated for 2 h
with primary antibodies mouse anti-GFP conjugated with FITC (1/50),
goat anti-human troponin I (1/50) and goat anti-troponin T–C (1/50),
all from Santa Cruz Biotechnology (CA, USA), rabbit anti-human
desmin (1/10) (Sigma-Aldrich, Missouri, USA) and rabbit anti-human
von Willebrand factor (1/200) (Sigma-Aldrich, Missouri, USA). The
sections were washed with TBS +0.1% triton, blocked with 10 mM
TBS containing 0.1% triton and 5% goat serum for 40 min and
incubated with secondary antibodies rabbit anti-goat IgG Texas Red
(Santa Cruz Biotechnology, CA, USA) (1/100), goat anti-rabbit IgG
(Molecular Probes, Oregon, USA) (1/400) for 1 h and 30 min at room
temperature. Nuclei were stained with 4′,6-diamino-2 phenylindole
(DAPI) and the slides were mounted using ﬂuorescence mounting
medium (Dako, CA, USA). The anti-GFP was used in the sections of
animals that were transplanted with cells transduced with the GFP
gene. The controls of the immunohistochemical reaction were made
using only the secondary antibody. Slides were analyzed in the E-600
Nikon microscope and images captured using the camera-CoolSNAP
PRO cf (Media Cybernetics) and Image Pro-Plus software (Diagnostic
Instruments).
Indirect immunoﬂuorescence
After the short SNAP exposure, cells were ﬁxed with 4% PFA and
then incubated with anti-nitrosocysteine (1/400) (Sigma-Aldrich,
Missouri, USA), overnight at 4 °C, in a humidiﬁed chamber. The
secondary antibody used was anti-rabbit IgG-Alexa 488 (1/600)
(Molecular Probes, Oregon, USA), in PBS containing 0.01% saponin
(Sigma-Aldrich, Missouri, USA), during 40 min at 4 °C. Actin was
labeled with phalloidin conjugated with Texas red (Sigma-Aldrich,
Missouri, USA). In some experiments, 2 mM HgCl2 was added to the
cells for 30 min, before the ﬁxation step, to analyze the speciﬁcity of
the anti-nitrosocysteine to the nitrosocysteine epitope. Images were
captured by a confocal microscopy (Nikkon, Eclipse 800 equipped
with a Biorad camera, Radianna 2100).
GSH and GSSG determination
Cells (treated in T75 ﬂasks) were pelleted and stocked at −80 °C
until analysis. For the GSH and GSSG determination, the light-protected
pelletswere thawed in ice, and suspended in 80 μL of a buffer consisting
of 50 mM phosphate pH 2.7, 50 μM sodium octanosulfonate (Sigma-
Aldrich, Missouri, USA). Cells were lysed by 3 freeze-thaw cycles in
liquid nitrogen/water bath. Lysates were centrifuged (10,000 rpm at
4 °C for 5 min) and the supernatants were 0.22 μm-ﬁltered. Thirty
microliters of the supernatants were injected in an HPLC Shimadzu
system consisting of a quaternary pump (LC20AD) controlled by the LC
Solution software, a manual injector (Rheodyne 7125), and a coulo-
metric detector (ESA Chelmsford), operating at 470 and 910 mV, for
GSH and GSSG detection, respectively.Intracellular levels of cGMP
Cells were treated as described in 24 wells plates (TPP, Trasadin-
gen, Switzerland). Cyclic GMP levels were assessed by a commercial
kit (GE Healthcare), according to the manufacturer.
Statistical analysis
This work has a primary outcome based on analysis of immuno-
histochemistry for in vivo evaluation of expression of neovasculariza-
tion and muscle markers and secondary in the evaluation of
ventricular function with the data obtained from an ejection fraction
of the left ventricle. Statistical analysis was performed by a non-
parametric Kruskal Wallis test for the assessment of ejection fraction
of the three study groups and by non-parametric Wilcoxon test to
compare pre and post ejection fraction within each group. The data
were analyzed with the software Statistica 8.0. The GSH/GSSG ratios
were analyzed by one way ANOVA, using GraphPad Prism software.
Results
The myocardial-infarcted animals were divided into three groups:
(A) control; animals that were transplanted with medium (n=4) (B)
animals that received ADSCs treated with SNAP (n=9) and (C)
animals that received untreated ADSCs (n=7). Some ADSCs samples
were transducedwith the GFP gene. A total of eight rats from groups B
and C were transplanted with GFP-transduced cells. The efﬁciency of
transduction with GFP gene was 28 and 31% for SNAP-treated and
untreated ADSCs, respectively (data not shown).
There was a signiﬁcant difference between groups with respect to
absolute difference in the pre and post transplant ejection fraction. A
signiﬁcant difference between B and C (p=0.008) was found, while
groups A and C (p=0.249) presented similar behavior (Fig. 1). This
data suggests that SNAP exposure to the ADSCs had a role in the ﬁnal
functional outcome. The ventricular remodeling occurred in all groups
measured by the increment of ventricular size. On average, this
variation was 18.8% in group A, 16.4% in group B and 17.1% in group C
(p=0.907). Although group B presented the lowest increment of
ventricular size, no signiﬁcant difference was observed between
groups. In addition, therewas no difference between groups regarding
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(p=0.999; data not shown).
The ejection fractions of animals in groups B and C that were
transplanted with GFP-transduced cells were compared to determine
if GFP transduction could have negatively inﬂuenced the ejection
fraction by providing an early cell death of transplanted ADSCs.
Although some GFP expression could be detected in the infarcted
region of all transplanted rats (Fig. 2), no difference in ejection
fraction was found between these two transplanted groups
(p=0.518), indicating that transplanted cells were integrated to the
injured tissue and that cardiac function was independent on GFP
expression.
To investigate if SNAP-treated cells were more prone to differen-
tiate into cardiac cells in the infarcted area, we analyzed the
expression of desmin, troponin T–C and troponin I by immunohisto-
chemistry. Positive cells to desmin were observed in both groups, B
and C in regions with and without myocardial infarct, i.e., with and
without transplanted cells (data not shown). These results indicate
that desmin is a nonspeciﬁc marker and could not be considered
appropriate for analysis of expression of cardiac proteins in
transplanted cells. The presence of troponin I was observed in the
infarcted area of both B and C groups (Fig. 3a, b). A speciﬁc marker to
cardiac cells, troponin T–C, was predominantly present in the
infarcted region of the animals in group B (Fig. 3c, d). The anti-von
Willebrand, speciﬁc for endothelial cells, was observed in cells around
blood vessels in infarcted and non-infarcted (data not shown) regions
in both groups B and C, but more prominently in SNAP-treated cells
(Fig. 3e, f). It was not observed unspeciﬁc staining by secondary
antibodies. A semi-quantitative analysis was carried out to evaluate
the number of vessels in the infarcted region of animals from groups B
and C. Sixty-eight random ﬁelds were counted in both groups, and a
greater number of vessels (n=81) was observed in group B whenFig. 2. GFP expression in ADSCs-transplanted infarcted myocardium. Indirect immunoﬂuo
untreated (a) and SNAP-treated ADSCs (b, c). In subpanel (d) the image is magniﬁed fromcompared with group C (n=63) which might reﬂect the more
extensive von Willebrand factor staining in group B.
So far, the results demonstrate that transplantation of SNAP-treated
ADSCs, compared with transplantation of untreated ADSCs, induces an
improvement in cardiac ejection fraction, an increased cardiac expres-
sion of troponin T–C and von Willebrand factor, and an increased
neovascularization. Next, we aimed to analyze the early events triggered
by SNAP in ADSCs, which could be associated with the above effects.
Since NO activates guanylate cyclase (GC), leading to the production of
cGMP,wemeasured its intracellular level 40 min after exposure to SNAP.
No signiﬁcant difference between control (untreated) and SNAP-treated
ADSCs was found (676 versus 710 fmol/well, respectively, n=2). We
employed1 μMDEA/NO, a compound that spontaneously releasesNO, as
a positive control. With this NO donor, cGMP levels increased to
976 fmol/well. This result demonstrates that SNAPdoesnot induce cGMP
production in ADSCs under our experimental conditions. Thus, an
alternative pathway toNO signaling is a cGMP-independentmechanism,
relying on protein S-nitrosation. Indeed, the images obtained with anti-
nitrosocysteine antibody show an intense immunostaining, with a
granular pattern dispersed in the cytoplasm, as determined by the
extension of actin labeling with phalloidin (Fig. 4). Control cells, i.e., not
exposed to SNAP, showed no anti-nitrosocysteine immunostaining
(Fig. 4). To investigate whether the observed reaction was due to
nitrosocysteine residues recognition,we incubated theﬁxed treated cells
with HgCl2, to disrupt the nitrosocysteine bond. Indeed, no staining was
observed after this incubation (datanot shown), conﬁrming the antibody
speciﬁcity to nitrosocysteine epitopes.
Since NO-derived species are able to alter the redox environment
of the cell, we assessed whether SNAP exposure could alter the
cellular redox state, determined by the GSH/GSSG ratio. Our results
indicate that SNAP decreases the GSH/GSSG ratio in ADSCs by ca. 50%
compared to the untreated cells (Fig. 5).rescence indicates the presence of GFP-transduced ADSCs (green) in infarcted area of
subpanel (c).
Fig. 3. Expression of troponin I, troponin T–C and von Willebrand factor in infarcted cardiac tissue after ADSCs transplantation. SNAP-treated (a, c, e) and untreated (b, d, f) ADSCs
were transplanted in the infarcted myocardium and the expression of troponin I (a, b), troponin T–C (c, d) and von Willebrand factor (e, f) was analyzed by indirect
immunoﬂuorescence.
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Cellular therapy has emerged as an alternative to cardiac repair and
formation of new blood vessels (Pittenger and Martin, 2004). Based on
studies showing that NO utilization could facilitate cardiomyogenesis
(Kanno et al., 2004) and that treatment of ADSCs with NO agents
increases the expression of cardiac speciﬁc genes (Rebelatto et al.,
2009), our focus was to study the effects of SNAP-treated ADSCs
transplantation on cardiac repair after myocardial infarct inWistar rats.
In this study, a signiﬁcant increase in the ejection fraction was
observed in the group that received ADSCs treated with SNAP
compared with the group that received untreated ADSCs. We did
not observe a signiﬁcant difference in the ejection fraction variation
between groups A (control) and C (transplanted with untreated
ADSCs), in contrast to other studies which show that mesenchymal
stem cell transplantation can improve cardiac function in different
experimental models (Caplan, 2009; Dai et al., 2005; Nagaya et al.,2005; Strem et al., 2005; Valina et al., 2007). Differences between
these publications and our results can be explained bymethodological
differences such as isolation and cultivation techniques (Giordano
et al., 2007), methods of infarct induction, moment of transplant after
infarction, route of infusion and number of transplanted cells.
Despite promising results in the recovery of ventricular function
with mesenchymal stem cell transplantation, some studies have not
shown positive results. Van der Bogt et al. (2009) performed cellular
transplant with bone marrow mesenchymal stem cells and ADSCs in
rats with myocardial infarction and did not observe beneﬁts on
ejection fraction, in line with our results. The low number of
transplanted cells, 5×105, might have interfered in the result. We
transplanted 1×106 cells by intramyocardial infusion. Possibly, a
higher number of transplanted stem cells could result in a signiﬁcant
functional improvement. Indeed, Nagaya et al. (2005) observed that
satisfactory increments of ejection fraction were obtained only after
increasing the number of stem cells to 5×106.
Fig. 4. Protein S-nitrosation by SNAP-treatment in ADSCs. Cells were untreated (a) or treated with 0.2 mM SNAP (b) during 40 min. After ﬁxation and permeabilization, actin was
labeled with phalloidin conjugated with Texas Red. The reaction was performed with anti-nitrosocysteine antibody and rabbit anti-IgG conjugated with Alexa 488.
154 G.R.M. Berardi et al. / Experimental and Molecular Pathology 90 (2011) 149–156We aimed to investigate the transplant of pre-committed ADSCs for
the cardiac phenotype. Other studies showed that committed cells could
lead to increased cytoprotectioneffects of cardiomyocytes present in the
heart and to increased therapeutic efﬁciency ofmesenchymal stem cells
in myocardial regeneration (Chamberlain et al., 2007). Mazo et al.
(2008) had demonstrated that undifferentiated ADSCs were more
efﬁcient than predifferentiated ADSCs to cardiac regeneration. These
differences can be related to different methods of predifferentiation
used in each study.We chose the nitrosothiol SNAP, since this agent had
beenpreviously shown to increase cardiomyogenesis in both embryonic
and adult stem cells (Kanno et al., 2004; Rebelatto et al., 2009). We
hypothesized that cardiomyogenesis might have been facilitated by the
ADSCs pre-commitment. Here, we demonstrated a signiﬁcant increase
in the ejection fraction in the group that received ADSCs treated with
SNAP compared with the group that received untreated ADSCs. This
increase in contractile function indicates that SNAP-treated cells
contribute to the improvement of the damaged area, since we have
observed an increased expressionof some cardiacmusclemarkers in theFig. 5. Decreased intracellular GSH/GSSG ratio by SNAP treatment in ADSCs.
Representative chromatograms of the simultaneous detection of GSH (peak 1,
470 mV trace) and GSSG (peak 2, 910 mV trace) in ADSCs cytosolic fraction are
shown. Inset shows the GSH/GSSG ratio in control and SNAP-treated ADSCs. The values
are representative of 5 independent experiments. *Pb0.05.infarcted area. Troponin I was expressed in untreated and SNAP-treated
ADSCs. Due to the small number of positive cells and the antibody
speciﬁty for the human protein, we suggest that cells expressing
troponin I were the transplanted human ADSCs. However, it was not
possible to visualize the co localization of GFP and troponin I-positive
cells. The anti-troponin T–C utilized is speciﬁc for cardiac tissue and its
expression was observed in ADSCs treated with SNAP and only in the
infarcted area. Thus, we suggest that SNAP had acted on the pre-
differentiation of ADSCs to muscular cells. The expression of cardiac
muscular proteins by ADSCs has been described after differentiation
induction by several methods. For example, Zuk et al. (2002) had
demonstrated that ADSCs in vitro could express myogenic transcription
factor 1 (myod1), desmin, myogenin, myogen regulator factor and
myosin heavy chain (MHC) after addition of hydrocortisone. Also, we
have demonstrated the expression of cardiac α-actin, troponin T,
troponin I and connexin-43 on ADSCs and bone marrow mesenchymal
stem cells after SNAP addition (Rebelatto et al., 2009) and the
improvement of cardiac function of infarcted rats has been associated
with expression of α-MHC, β-MHC, α-actin and myosin light chain
(MLC2v) after 30 days of transplant (Nagaya et al., 2005).
In addition, our results show that SNAP-treated cells were either
more prone to differentiate to endothelial cells or that they induced
other tissue cells to differentiate into endothelial cells, by a paracrine
signaling for instance. Our data showed more cells expressing von
Willebrand factor and organized in vascular units in infarction area of
animals that received treated ADSCs than in the group that received
untreated cells. Recent studies suggest that mesenchymal stem cells
can be differentiating toward endothelial cells (Fraser et al., 2006;
Kinnaird et al., 2004; Tang et al., 2006). However, we were unable to
co-localize GFP and von Willebrand factor in our experiments. This is
not surprising considering that the efﬁciency of transduction was
approximately 30%, and about 3% of these cells remain at the lesion
site (Freyman et al., 2006). On the other hand, SNAP has been
associated with VEGF increment (Maulik, 2006) and this marker is
involved in function improvement, vessels number increment and
remodeling limitation as demonstrated by Sadat et al. (2007). These
authors had demonstrated that ADSCs secrete angiogenic factors that
are responsible for vascular formation and cellular protection. Also,
Tang et al. (2005) had demonstrated that ventricular function
increment and vessels formation after mesenchymal cell transplant
were associatedwith elevation of VEGF, ﬁbroblast growth factor (FGF)
and stem cell derived factor 1-α (SDF-1α) expression. We had
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after SNAP exposure (Rebelatto et al., 2009). Indeed the vasculogen-
esis has been more often observed than the differentiation in muscle
cells (Kamihata et al., 2002).
Here we showed that SNAP induces ADSCs S-nitrosation that may
contribute to the functional effects observed.We did not identiﬁed the
proteins modiﬁed by SNAP in ADSCs, but in endothelial cells, S-
nitrosation by exogenous NO donors, like DEA/NO, takes place mainly
inmitochondrial proteins, presenting a staining pattern similar to that
observed by us (Yang and Loscalzo, 2005). Recently, SNAP has been
shown to stabilize HIF1α, leading to VEGF expression, by a
mechanism dependent on HIF1 S-nitrosation (Park et al., 2008).
SNAP is anitrosothiolwhichhasbeendescribed to releaseNO, leading
to cardiovascular beneﬁts, such as vasodilation (Moncada and Higgs,
1993; Nathan, 1992) and also protection against oxidative stress
(Monastyrskaya et al., 2002).However, its chemical properties, regarding
NO release, are quite complex, and are extremely dependent on the
chemical environment (Janssens et al., 1999) such as the presence of
thiols (Hu and Chou, 2006). SNAP itself cannot cross the cell membrane
(Zhang andHogg, 2005). Thus, it can be suggested that SNAP-derivedNO
enters the cell, possibly by transnitrosation mediated by membrane
proteins (Zai et al., 1999). NO or NO-derived species then nitrosates
intracellular thiols, such as glutathione. Nitrosoglutathione may then
further react with other biomolecules, and becomes oxidized, decreasing
theGSH/GSSG ratio. These transnitrosation reactionsmay account for the
lack of GC activation observed in our experiments. Moreover, nitroso-
proteinsmay transfer theNOmoiety to other thiols, acting asNOcarriers/
storage. It has been demonstrated in endothelial cells that the half-life of
nitrosoproteins is about 1 h (Yang and Loscalzo, 2005).
Finally, the SNAP-induced oxidative redox state in ADSCs is in
agreement with the ﬁndings described by Jones (for a review, see
Jones, 2006). It has been demonstrated that a slightly oxidative
reduction potential, measured by the intracellular concentrations of
glutathione and glutathione disulﬁde accompanies the differentiation
phenotype, probably by altering the redox state of target protein
modules involved in transcription. On the other hand, more reduced
potentials are associated with cell proliferation. Thus, the decreased
GSH/GSSG ratio found after SNAP treatment in ADSC may be an
important factor to induce differentiation.
In conclusion, this study indicates that transplanted SNAP-treated
ADSCs induce a functional improvement and neovascularization in
rats that underwent severe myocardial infarction, possibly by events
involving ADSCs protein S-nitrosation and decreased GSH/GSSG ratio.
Speciﬁc proteins involved in this process remain to be identiﬁed.
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